Non-invasive algorithm of enhanced liver fibrosis and liver stiffness measurement with transient elastography for advanced liver fibrosis in chronic hepatitis B

Alimentary Pharmacology and Therapeutics

Volumn 39, Issue 2, 2014, Pages 197-208

  Wong, G L H ^a   Chan, H L Y ^a   Choi, P C L ^a   Chan, A W H ^a   Yu, Z ^a   Lai, J W Y ^a   Chan, H Y ^a   Wong, V W S ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ALGORITHM; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC EQUIPMENT; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; ELASTOGRAPHY; ENHANCED LIVER FIBROSIS AND LIVER STIFFNESS MEASUREMENT ALGORITHM; FEMALE; HEPATITIS B; HISTOPATHOLOGY; HUMAN; LIVER EXAMINATION; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INVASIVE MEASUREMENT; PRIORITY JOURNAL; PROGNOSIS; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY;

ADULT; ALGORITHMS; BIOPSY; ELASTICITY IMAGING TECHNIQUES; FEMALE; HEPATITIS B, CHRONIC; HUMANS; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; ROC CURVE;

EID: 84890570907     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12559     Document Type: Article

References (37)

1. Chan HL, Sung JJ,. Hepatocellular carcinoma and hepatitis B virus. Semin Liver Dis 2006; 26: 153-61.
2. Wong VW, Chan SL, Mo F, et al,. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J Clin Oncol 2010; 28: 1660-5.
3. Wong GL, Chan HL, Chan HY, et al,. Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment. Gastroenterology 2013; 144: 933-44.
4. Chan HL, Wong GL, Wong VW,. A review of the natural history of chronic hepatitis B in the era of transient elastography. Antivir Ther 2009; 14: 489-99.
5. European Association For The Study Of The L. EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-85.
6. Liaw YF, Kao JH, Piratvisuth T, et al,. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 2012; 6: 531-61.
7. Lok AS, McMahon BJ,. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-2.
8. Rockey DC, Caldwell SH, Goodman ZD, et al,. Liver biopsy. Hepatology 2009; 49: 1017-44.
9. Wong GL, Wong VW, Choi PC, et al,. Development of a non-invasive algorithm with transient elastography (Fibroscan) and serum test formula for advanced liver fibrosis in chronic hepatitis B. Aliment Pharmacol Ther 2010; 31: 1095-103.
10. Wong GL,. Transient elastography: Kill two birds with one stone? World J Hepatol 2013; 5: 264-74.
11. Wong GL, Wong VW, Choi PC, et al,. Increased liver stiffness measurement by transient elastography in severe acute exacerbation of chronic hepatitis B. J Gastroenterol Hepatol 2009; 24: 1002-7.
12. Wong VW, Vergniol J, Wong GL, et al,. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 2010; 51: 454-62.
13. Wong GL, Chan HL, Choi PC, et al,. Association between anthropometric parameters and measurements of liver stiffness by transient elastography. Clin Gastroenterol Hepatol 2013; 11: 295-302. e1-3.
14. Chan HL, Wong GL, Choi PC, et al,. Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B. J Viral Hepat 2009; 16: 36-44.
15. Lichtinghagen R, Pietsch D, Bantel H, et al,. The Enhanced Liver Fibrosis (ELF) score: Normal values, influence factors and proposed cut-off values. J Hepatol 2013; 59: 236-42.
16. Parkes J, Roderick P, Harris S, et al,. Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. Gut 2010; 59: 1245-51.
17. Chan HL, Chui AK, Lau WY, et al,. Factors associated with viral breakthrough in lamivudine monoprophylaxis of hepatitis B virus recurrence after liver transplantation. J Med Virol 2002; 68: 182-7.
18. Wong GL, Wong VW, Chan HY, et al,. Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HBeAg-seroconversion in chronic hepatitis B patients at 3 years. Aliment Pharmacol Ther 2012; 35: 1326-35.
19. Bedossa P, Poynard T,. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289-93.
20. Siemens Healthcare Diagnostics Inc. ADVIA centaur enhanced liver fibrosis (ELF) test specifications. Available at: http://healthcare.siemens.com/siemens- hwem-hwem-ssxa-websites-context-root/wcm/idc/groups/public/@global/documents/ download/mdaw/mtc2/~edisp/xc1-elf-spec-sheet-00046572.pdf. Accessed July 19, 2013.
21. Wong GL, Wong VW, Choi PC, et al,. Assessment of fibrosis by transient elastography compared with liver biopsy and morphometry in chronic liver diseases. Clin Gastroenterol Hepatol 2008; 6: 1027-35.
22. Wong VW, Wong GL, Chan FK,. Liver stiffness measurement: simplicity is prerequisite for reliability. Gastroenterology 2013; 144: 243-4.
23. Wong GL, Chan HL, Mak CH, et al,. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology 2013; 58: 1537-47.
24. Bruix J, Sherman M,. American Association for the Study of Liver D. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-2.
25. Pinzani M, The ELF,. panel: a new crystal ball in hepatology? Gut 2010; 59: 1165-7.
26. Castera L, Pinzani M,. Biopsy and non-invasive methods for the diagnosis of liver fibrosis: does it take two to tango? Gut 2010; 59: 861-6.
27. de Ledinghen V, Vergniol J, Barthe C, et al,. Non-invasive tests for fibrosis and liver stiffness predict 5-year survival of patients chronically infected with hepatitis B virus. Aliment Pharmacol Ther 2013; 37: 979-88.
28. Everson GT, Shiffman ML, Hoefs JC, et al,. Quantitative liver function tests improve the prediction of clinical outcomes in chronic hepatitis C: results from the Hepatitis C Antiviral Long-term Treatment Against Cirrhosis Trial. Hepatology 2012; 55: 1019-29.
29. Bedossa P, Dargere D, Paradis V,. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 38: 1449-57.
30. TFMCS Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology 1994; 20: 15-20.
31. Mehta SH, Lau B, Afdhal NH, et al,. Exceeding the limits of liver histology markers. J Hepatol 2009; 50: 36-41.
32. Wong GL,. Update of liver fibrosis and steatosis with transient elastography (Fibroscan). Gastroenterol Rep 2013; doi: 10.1093/gastro/got007 [Epub ahead of print].
33. Forns X, Ampurdanes S, Llovet JM, et al,. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002; 36: 986-92.
34. Hui AY, Chan HL, Wong VW, et al,. Identification of chronic hepatitis B patients without significant liver fibrosis by a simple noninvasive predictive model. Am J Gastroenterol 2005; 100: 616-23.
35. Wai CT, Cheng CL, Wee A, et al,. Non-invasive models for predicting histology in patients with chronic hepatitis B. Liver Int 2006; 26: 666-72.
36. Sandrin L, Fourquet B, Hasquenoph JM, et al,. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003; 29: 1705-13.
37. Wong VW, Chan HL,. Severe acute exacerbation of chronic hepatitis B: a unique presentation of a common disease. J Gastroenterol Hepatol 2009; 24: 1179-86.